AC Immune KOL Webinar on the Potential Benefits of Vaccines for Alzheimer’s and Parkinson’s Diseases
- Vaccines can provide safe, long-lasting immunity, and logistical advantages compared to other treatment modalities
- Integrating its precision medicine approach,
AC Immuneis advancing three clinical-stage vaccines targeting Tau, Abeta and α-synuclein
- Precisely targeted active immunotherapy may enable prevention of pathological pathways before the occurrence of irreversible neuronal damage
Over 180 participants from the investment and biopharmaceutical industries registered to attend the webinar, which included presentations from
During the event, presenters discussed how vaccination can provide safe, long-lasting immunity, and logistical advantages over other treatment modalities. A summary of this discussion is provided below:
- Vaccines stimulate antibody responses that simultaneously target multiple pathological epitopes, providing potential for higher efficacy compared to agents targeting single epitopes
- Vaccines enhance the individual immune response by allowing the immune system to optimize antibodies for a specific proteinopathy over time
- Vaccine-induced antibodies are produced by the patient’s own immune system, which confers continual functionality advantages over exogenously prepared antibodies
- Vaccines provide long-lasting immune activation and consistent antibody titers, which may improve safety and long-term efficacy compared to passive immunotherapies
- Vaccination may enable annual or bi-annual dosing schedules that improve costs and patient compliance
During the webinar,
- ACI-35.030, an anti-phospho-Tau vaccine derived from AC Immune’s SupraAntigen®-V platform and partnered with
Janssen Pharmaceuticals, Inc.Previously reported interim data from an ongoing Phase 1b/2 trial of ACI-35.030 in Alzheimer’s disease provided clinical validation for SupraAntigen®-V by showing no safety concerns, robust immunogenicity, and evidence of a lasting immune response that supports a disease prevention approach. The disclosure of late-stage development plans for ACI-35.030 is expected in 2022.
- ACI-24.060, an anti-Abeta vaccine that targets the protein’s two most toxic forms, pyroglutamate-Abeta and oligomeric Abeta. ACI-24.060 is being evaluated in the Phase 1b/2 ABATE study in patients with Alzheimer’s disease and individuals with Down syndrome. Interim data from the trial, which has an innovative, biomarker-based design that can accelerate time to clinical proof-of-concept and the transition to pivotal studies, are expected in 2022.
- ACI-7104, an anti-α-synuclein vaccine being developed as a treatment for Parkinson’s disease and other α-synucleinopathies.
AC Immuneexpects to initiate an adaptive, biomarker-based Phase 2 trial of ACI-7104 in Parkinson’s disease patients in 2022.
Dr. Andrea Pfeifer, CEO of AC Immune commented: “Our clinical-stage vaccines target three key hallmarks of neurodegenerative disease. We believe these programs, together with our cutting-edge diagnostic imaging agents, position
About the SupraAntigen® platform
AC Immune’s clinically validated SupraAntigen® platform uses proprietary liposomes to rapidly generate novel vaccines (SupraAntigen-V) for active immunization as well as best-in-class monoclonal antibodies (SupraAntigen-A) for passive immunization against key neurodegenerative disease targets. Antibodies generated by the platform are highly specific for the pathological conformations of misfolded proteins and have shown strong safety. The SupraAntigen® platform has successfully generated two vaccines and two antibody candidates that have been validated in clinical studies and has led to multiple global partnerships with world-leading pharmaceutical companies. In addition to targeting Abeta and Tau,
SupraAntigen® is a registered trademark of
For further information, please contact:
Phone: +41 21 345 91 34
Phone: +41 21 345 91 91
Phone: +1 609 516 5761
Phone: +1 212 915 2577
Forward looking statements
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the
Source: AC Immune SA